125 related articles for article (PubMed ID: 38072417)
41. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
[TBL] [Abstract][Full Text] [Related]
42. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
44. Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
Lung Cancer; 2015 May; 88(2):131-8. PubMed ID: 25769882
[TBL] [Abstract][Full Text] [Related]
45. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
Peter B; Gleixner KV; Cerny-Reiterer S; Herrmann H; Winter V; Hadzijusufovic E; Ferenc V; Schuch K; Mirkina I; Horny HP; Pickl WF; Müllauer L; Willmann M; Valent P
Haematologica; 2011 May; 96(5):672-80. PubMed ID: 21242189
[TBL] [Abstract][Full Text] [Related]
46. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
47. Megakaryocyte polyploidization is associated with decreased expression of polo-like kinase (PLK).
Yagi M; Roth GJ
J Thromb Haemost; 2006 Sep; 4(9):2028-34. PubMed ID: 16805859
[TBL] [Abstract][Full Text] [Related]
48. Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress.
Uckun FM; Ozer Z; Qazi S; Tuel-Ahlgren L; Mao C
Br J Haematol; 2010 Mar; 148(5):714-25. PubMed ID: 19912216
[TBL] [Abstract][Full Text] [Related]
49. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Yoshida-Sakai N; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Kimura S
Int J Cancer; 2022 Apr; 150(7):1184-1197. PubMed ID: 34913485
[TBL] [Abstract][Full Text] [Related]
50. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
51. SPAT-1/Bora acts with Polo-like kinase 1 to regulate PAR polarity and cell cycle progression.
Noatynska A; Panbianco C; Gotta M
Development; 2010 Oct; 137(19):3315-25. PubMed ID: 20823068
[TBL] [Abstract][Full Text] [Related]
52. Polo-like kinases in AML.
Berg T; Bug G; Ottmann OG; Strebhardt K
Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
[TBL] [Abstract][Full Text] [Related]
53. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
Cortes J; Podoltsev N; Kantarjian H; Borthakur G; Zeidan AM; Stahl M; Taube T; Fagan N; Rajeswari S; Uy GL
Int J Hematol; 2021 Jan; 113(1):92-99. PubMed ID: 32951163
[TBL] [Abstract][Full Text] [Related]
54. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
55. Down-regulation of WT1/+17AA gene expression using RNAi and modulating leukemia cell chemotherapy resistance.
Shen H; Xu W; Wu Z; Tang H; Xie Y; Zhong X
Haematologica; 2007 Sep; 92(9):1270-2. PubMed ID: 17768125
[TBL] [Abstract][Full Text] [Related]
56. Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients.
Goroshchuk O; Vidarsdottir L; Björklund AC; Hamil AS; Kolosenko I; Dowdy SF; Palm-Apergi C
Sci Rep; 2020 Feb; 10(1):2688. PubMed ID: 32060361
[TBL] [Abstract][Full Text] [Related]
57. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
58. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies.
Katzenellenbogen RA; Baylin SB; Herman JG
Blood; 1999 Jun; 93(12):4347-53. PubMed ID: 10361133
[TBL] [Abstract][Full Text] [Related]
59. Channel Nucleoporins Recruit PLK-1 to Nuclear Pore Complexes to Direct Nuclear Envelope Breakdown in C. elegans.
Martino L; Morchoisne-Bolhy S; Cheerambathur DK; Van Hove L; Dumont J; Joly N; Desai A; Doye V; Pintard L
Dev Cell; 2017 Oct; 43(2):157-171.e7. PubMed ID: 29065307
[TBL] [Abstract][Full Text] [Related]
60. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
